Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Faravelli
Ilaria Faravelli, Lodi IT
| Patent application number | Description | Published |
|---|---|---|
| 20100226865 | TOOTHPASTE COMPOSITION - A toothpaste composition comprising a surfactant, an abrasive, a humectant, triglyceride oil, a carboxylated polysaccharide, and a sulphated or sulphonated polysaccharide and the use of a sulphated or sulphonated polysaccharide, in particular a carrageenan, to improve the in-use foam quality of a toothpaste. | 09-09-2010 |
Laura Faravelli, Garbagnate Milanese (mi) IT
| Patent application number | Description | Published |
|---|---|---|
| 20110046129 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators - 2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented. | 02-24-2011 |
Laura Faravelli, Garbagnate Milanese IT
| Patent application number | Description | Published |
|---|---|---|
| 20080319057 | 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators - 2-Phenylethylamino substituted carboxamide derivatives of formula (I); wherein J, W, R | 12-25-2008 |
| 20100324141 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF - A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]-propanamides and their salts with pharmaceutically acceptable acids with a high degree of purity, i.e. with a content of dibenzyl derivatives impurities lower than 0.03% by weight. The process is carried out by submitting a Schiff base intermediate to a reduction reaction with a reducing agent in an amount of organic solvent to allow the formation (and presence during a substantial portion of the reduction reaction) of a suspension of the Schiff base. | 12-23-2010 |
| 20110014304 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS - The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders. | 01-20-2011 |